Skip to main content

Live Arrowhead Research Corporation Share Price Chart

O 43.33H 43.33L 43.33

Arrowhead Research Corporation Performance Overview

Days Range
▼
$42.95Low
$44.78High

Markets Today

Previous Close$43.11
Open$43.33
Volume1,059,715
Day's Range$42.95 - $44.78
52W Range$37.06 - $95.49
Market Cap$6.08 B

Historical Performance

1M Returns-24.67
3M Returns-51.78
6M Returns-41.09
1Y Returns+10.62
5Y Returns-39.38
10Y Returns+891.03

Arrowhead Research Corporation Fundamentals

Market Cap$6.08 B
Dividend yield0.00
PE Ratio0.00
PEG RatioN/A
Revenue$450.82 M
ROE TTM-0.01
EPS TTM$-2.24
Quarterly Earnings Growth YOYN/A
PB Ratio17.42
EBITDA$-680.55 M
Profit Margin-160.64
Market Cap$6.08 B
Dividend yield0.00
PE Ratio0.00
PEG RatioN/A
Revenue$450.82 M
ROE TTM-0.01
EPS TTM$-2.24
Quarterly Earnings Growth YOYN/A
PB Ratio17.42
EBITDA$-680.55 M
Profit Margin-160.64

Arrowhead Research Corporation Profit & Loss

Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Total Revenue +$27.77 M$256.47 M$264.03 M$73.74 M$75.25 M$37.79 M
Gross Profit +$27.77 M$256.47 M$264.03 M$73.74 M$75.25 M$37.79 M
Operating Income -$165.55 M$44.11 M$40.81 M-$141.26 M-$170.09 M-$436.63 M
EBITDA -$159.33 M$50.49 M$47.20 M-$134.89 M-$163.43 M-$429.42 M
Interest Expense -$24.38 M-$21.69 M-$22.50 M-$23.85 M-$24.56 M-$22.80 M
Depreciation $6.22 M$6.39 M$6.39 M$6.37 M$6.66 M$7.21 M
Income Before Tax -$179.09 M$36.12 M$28.27 M-$137.56 M-$178.91 M-$435.71 M
Income Tax Expense -$437.00 K$20.00 M$29.00 K$7.00 K$11.00 K-$6.83 M
Net Income +-$178.65 M$16.12 M$28.24 M-$137.57 M-$178.92 M-$428.88 M
Net Profit Margin -643.4%6.29%10.7%-186.57%-237.75%-1134.8%

Arrowhead Research Corporation Financials Balance Sheet In USD

Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Share Capital $230.00 K$231.00 K$233.00 K$236.00 K$237.00 K$237.00 K
Reserve & Surplus -$1.60 B-$1.62 B-$1.59 B-$1.73 B-$1.92 B-$2.36 B
Non-Current Liabilities $666.28 M$686.39 M$694.06 M$1.37 B$1.36 B$1.38 B
Current Liabilities $194.53 M$195.49 M$347.43 M$295.22 M$283.35 M$311.34 M
Total Liabilities $860.81 M$881.88 M$1.04 B$1.67 B$1.65 B$1.69 B
Fixed Assets $388.33 M$389.38 M$385.02 M$380.83 M$378.89 M$376.47 M
Current Assets $946.92 M$950.64 M$1.17 B$1.84 B$1.67 B$1.29 B
Total Assets $1.38 B$1.39 B$1.60 B$2.27 B$2.11 B$1.74 B

Arrowhead Research Corporation Cash Flow

Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Net Income -$178.65 M$16.12 M$28.24 M-$137.57 M-$178.92 M-$428.88 M
Operating Cash Flow -$154.72 M$20.49 M$13.48 M$84.44 M-$177.47 M-$192.40 M
Investing Cash Flow $141.39 M$72.62 M-$23.74 M-$894.28 M$43.68 M$203.86 M
Financing Cash Flow -$42.68 M$3.67 M-$14.75 M$795.72 M-$449.00 K-$3.70 M
Change in Cash -$56.01 M$96.78 M-$25.01 M-$14.12 M-$134.24 M$7.76 M

Arrowhead Research Corporation Return Calculator

The Arrowhead Research Corporation stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Returns Estimator

Based on past performance of this fund

ENTER AMOUNT
$10,000
Select Duration
5Yrs
1 Yr5 Yrs
If you had invested $10,000 5 years ago, what would its value be today?$6,043
Invested Amount$10,000
Est. Returns$-3,957
Invest in USA Stock Today

About Arrowhead Research Corporation

Arrowhead Pharmaceuticals Inc develops medicines using its targeted RNAi molecule, TRiM, platform that uses a natural pathway to silence genes causing disease. It has commercialized Redemplo (plozasiran) as an adjunct to diet to reduce triglycerides (TGs) in adults with Familial Chylomicronemia Syndrome (FCS). Redemplo has received marketing authorization for FCS across the European Union, the USA, Canada, Australia, China, and the United Kingdom. It has several drug candidates in clinical trials ranging from early to late stage, including both partnered and wholly-owned candidates such as Zodasiran, Olpasiran, Fazirsiran, ARO-C3, and others being developed as therapies for various cardiometabolic, pulmonary, liver, neuromuscular, and other conditions. It operates as a single segment.

FAQs

Arrowhead Research Corporation (ARWR) share price as of November 19, 2026 is $42.97. If you are investing from India, you can always check the valuation in the INR before investing.
Yes, Indian Investors can invest in the Arrowhead Research Corporation (ARWR) Share by opening an international trading account with Angel One.
Purchasing Arrowhead Research Corporation (ARWR) share from India can be done by: Directly: By opening an international trading account with Angel One. The process would include KYC verification. The account activation takes a few minutes to a few hours, after which you can start buying Arrowhead Research Corporation (ARWR) by making deposits in US dollars. Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.
Yes, you can purchase fractional shares of Arrowhead Research Corporation (ARWR) or any other US company shares in Angel One for any dollar amount.
The market capitalization of Arrowhead Research Corporation on November 19, 2026, is $6.08 B.
Arrowhead Research Corporation operates in the Healthcare sector, specifically in the Healthcare industry.
In order to invest in Arrowhead Research Corporation (ARWR) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.). From start to end, the process is digital and can be seamless.